Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.

Revenue
+3.07%
EPS
−13.5%
Free cash flow
+29.8%
Total debt
−7.50%

Quarter to September 2026, against a year earlier

105.28 1.57 −1.47%
Market cap
$20.4B
P/E
26.5×
Fwd P/E
18.9×
Dividend yield
0.91%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100

Zimmer Biomet Holdings, Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 6:36 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 25, 2025: 3 added · 4 removed · 25 modified; 7 with only figures updated

  1. Modified · Overview

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (“CMFT”) products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. In this report, “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer collectively to Zimmer Biomet Holdings, Inc. and its subsidiaries. “Zimmer Biomet Holdings” refers to the parent company only.